Bartlomiej Wroblewski/iStock via Getty Images Quantinuum Is Still Primarily A Research Company Quantinuum, Inc. ( QNT ) has filed to raise continued operating capital via an IPO of its Class A common stock, according to an S-1 registration statement . The company is developing quantum computing technologies for clients worldwide. Its business is R&D-heavy, and QNT is burning through large amounts ...
Bartlomiej Wroblewski/iStock via Getty Images Quantinuum Is Still Primarily A Research Company Quantinuum, Inc. ( QNT ) has filed to raise continued operating capital via an IPO of its Class A common stock, according to an S-1 registration statement . The company is developing quantum computing technologies for clients worldwide. Its business is R&D-heavy, and QNT is burning through large amounts of cash as it seeks to transition to a full commercialization positioning, which may be some time in the future. What Does Quantinuum Do? Quantinuum is a unit of Honeywell ( HON ) that was created to combine Honeywell’s hardware technological development with Cambridge Quantum’s software capabilities to deploy quantum computers with commercial and governmental customers. The firm’s systems do things like help clients simulate risks, financial calculations, electronic structure analysis, and potentially many other uses. QNT believes the future of computing will be a combination of classical computers, accelerated compute and quantum compute. The company currently has a workforce of around 700 employees, with more than 450 holding advanced degrees. Revenue contribution in 2025 is shown in the pie charts below: SEC The firm is led by President and Chief Executive Officer Dr. Rajeeb Hazra, who has been with the company since February 2023 and was previously a senior executive at Micron Technology ( MU ) and Intel ( INTC ). The unit has received approximately $2.48 billion in fair market value investment in its history from Honeywell entities and Cambridge Quantum entities. What is Quantinuum Market? The global quantum computing market was an estimated $1.4 billion in 2024 and is forecast to exceed $4.2 billion by 2030, according to a market research report by Grand View Research. Its growth rate, if achieved, would represent a CAGR of 20.5% from 2025 to 2030, a very strong growth rate estimate. In 2024, the European region accounted for 33.8% of the global market share. The BFS...
Although President Trump's much-heralded "Most Favored Nation" drug policy promises to bring cheaper medication prices to Americans, it could come at the cost of the US losing its lead in biopharma innovation to China, according to a top executive of the pharmaceutical industry's main lobbying group. Speaking at the FT US Pharma and Biotech Summit in New York on Thursday, Pharmaceutical Research a...
Although President Trump's much-heralded "Most Favored Nation" drug policy promises to bring cheaper medication prices to Americans, it could come at the cost of the US losing its lead in biopharma innovation to China, according to a top executive of the pharmaceutical industry's main lobbying group. Speaking at the FT US Pharma and Biotech Summit in New York on Thursday, Pharmaceutical Research and Manufacturers of America (PhRMA) COO Lori Reilly indicated that depressed prices, in both the US and Europe, could negatively impact US drug R&D. She said that drug policies outside the US "undervalue innovation and [include] discriminatory practices." If we "import those types of policies and values and do nothing…that is an invitation to China to overtake the US in biopharma innovation." Reilly suggested that the Trump administration use some of its trade tools more, such as Section 301 of the Trade Act of 1974, which allows the US to levy tariffs and import restrictions against trade practices considered "unjustifiable" or "unreasonable." In March, the Office of the United States Trade Representative opened a 301 investigation into excess capacity and production in manufacturing sectors in 16 countries, including China, the European Union, Mexico, Japan, and India. During a panel discussion at the conference, members discussed how MFN could impact drug prices and how foreign countries may source their drugs from in the future. USC Sol Price School of Public Policy Associate Professor Alice Chen said that companies are driven by profit-maximizing strategies, so some may decide not to sell their drugs in Europe or participate in Medicare or Medicaid drug programs to avoid the impact of MFN. Reilly noted that MFN could lead to other countries buying more drugs from Chinese biopharma companies instead. The US "needs to make a concerted effort to have policy here…that respects intellectual property, free market policy to the extent we can, and [reforms] the FDA," such as u...
Getty Images In February 2026, I published my last article about the search and AI giant Alphabet Inc. ( GOOG ) and similar to many other companies from this sector and companies with a high exposure to AI, I was rather cautious about the stock as an investment. I argued in the article that Alphabet has great AI execution, but the investment case is weakening, and I wrote in my conclusion: Alphabe...
Getty Images In February 2026, I published my last article about the search and AI giant Alphabet Inc. ( GOOG ) and similar to many other companies from this sector and companies with a high exposure to AI, I was rather cautious about the stock as an investment. I argued in the article that Alphabet has great AI execution, but the investment case is weakening, and I wrote in my conclusion: Alphabet is performing great and is on its way to becoming not only the dominant search company but also one of the leaders in AI. We can be confident the business will continue to grow at a high pace, but the current stock price is already reflecting this growth potential, and therefore Alphabet remains a “Hold” at this point. However, it seems like I have been too pessimistic about the stock as Alphabet is continuing to grow its stock price at a high pace. Since my last article was published, the stock price increased almost 23%. This is not only a great performance over less than 3 months. The stock also outperformed the S&P 500, which increased about 7% in the same timeframe. In the following article I will argue that Alphabet is overvalued at this point and although such a great business is definitely not a “Sell” it is hard to argue for a “Buy” at these prices. Quarterly Results We start by looking at the last quarterly results, which were reported on April 29, 2026, and were great once again. Revenue increased from $90,234 million in Q1/25 to $109,896 million in Q1/26 – resulting in 21.8% year-over-year growth. We can also point out that quarterly revenue growth is accelerating in the last few years, which is a good sign. Data by YCharts Revenue from operations increased from $30,606 million in the same quarter last year to $39,696 million in this quarter – resulting in 29.7% year-over-year growth. Diluted net income per share increased even 81.9% year-over-year from $2.81 in Q1/25 to $5.11 in Q1/26. Finally, free cash flow declined from $18,953 million in the same quarter ...
Getty Images In February 2026, I published my last article about the search and AI giant Alphabet Inc. ( GOOG ) and similar to many other companies from this sector and companies with a high exposure to AI, I was rather cautious about the stock as an investment. I argued in the article that Alphabet has great AI execution, but the investment case is weakening, and I wrote in my conclusion: Alphabe...
Getty Images In February 2026, I published my last article about the search and AI giant Alphabet Inc. ( GOOG ) and similar to many other companies from this sector and companies with a high exposure to AI, I was rather cautious about the stock as an investment. I argued in the article that Alphabet has great AI execution, but the investment case is weakening, and I wrote in my conclusion: Alphabet is performing great and is on its way to becoming not only the dominant search company but also one of the leaders in AI. We can be confident the business will continue to grow at a high pace, but the current stock price is already reflecting this growth potential, and therefore Alphabet remains a “Hold” at this point. However, it seems like I have been too pessimistic about the stock as Alphabet is continuing to grow its stock price at a high pace. Since my last article was published, the stock price increased almost 23%. This is not only a great performance over less than 3 months. The stock also outperformed the S&P 500, which increased about 7% in the same timeframe. In the following article I will argue that Alphabet is overvalued at this point and although such a great business is definitely not a “Sell” it is hard to argue for a “Buy” at these prices. Quarterly Results We start by looking at the last quarterly results, which were reported on April 29, 2026, and were great once again. Revenue increased from $90,234 million in Q1/25 to $109,896 million in Q1/26 – resulting in 21.8% year-over-year growth. We can also point out that quarterly revenue growth is accelerating in the last few years, which is a good sign. Data by YCharts Revenue from operations increased from $30,606 million in the same quarter last year to $39,696 million in this quarter – resulting in 29.7% year-over-year growth. Diluted net income per share increased even 81.9% year-over-year from $2.81 in Q1/25 to $5.11 in Q1/26. Finally, free cash flow declined from $18,953 million in the same quarter ...
From drought to ping-pong size hail and unseasonable warmth, weather extremes have wheat farmers reaching for their phones to ring their insurance adjusters to assess the viability of their crops. Oklahoma farmer Dennis Schoenhals made the call a few weeks ago, after a storm hammered his wheat with icy chunks, bending the stalks in half, while only dropping an inch of rain. “We thought we were rea...
From drought to ping-pong size hail and unseasonable warmth, weather extremes have wheat farmers reaching for their phones to ring their insurance adjusters to assess the viability of their crops. Oklahoma farmer Dennis Schoenhals made the call a few weeks ago, after a storm hammered his wheat with icy chunks, bending the stalks in half, while only dropping an inch of rain. “We thought we were really going to have a good crop — the best crop we’d ever had — and then we got hit by hail,” he said. “According to the adjuster, we’ve had about 70% damage. We lost 70% of our yield.” But with just a week to go before he harvests, Schoenhals added, “It’s too late to bail.” So he’ll run his combine, salvaging what he can and tilling the rest as a way to improve the soil for the next crop. Farmers across Kansas — the US’s top wheat producing state — relayed similar stories this week as crop scouts with the Wheat Quality Council ’s annual crop tour fanned out to inspect fields of hard red winter wheat there, as well as in parts of Oklahoma and Nebraska. The group of 60 included grain buyers, agricultural economists and university researchers. Their reports validated farmers’ worries. Freezes and frost left patches of damage in some fields, while a persistent drought stunted plants, which have struggled to fill out in dry, crumbly soil even as warm temperatures have prompted them to mature earlier than usual. Diseases like wheat streak mosaic have only added to the problem. The conditions have many producers bracing for a tough harvest amid a drought that has swept across 71% of the nation’s winter wheat growing areas. The US Department of Agriculture this week estimated a 25% decline in US winter wheat production “primarily on sharply reduced Hard Red Winter production,” a variety preferred by Kansas growers. That forecast helped send wheat prices up by the daily trading limit on Tuesday — a surge that had some wheat buyers on the crop tour “sweating bullets,” according to Kan...
STAAR Surgical ( STAA ) stock price surged ~10% to $32.81 in just one day after a massive Q1 earnings beat, extending its monthly rally to around 20% as bulls cheered its strong China recovery and profit improvement. STAAR Surgical reported Q1 non-GAAP EPS of $0.48, beating estimates by $0.40, while revenue surged 119.5% YoY to $93.5M, topping analyst expectations by $14.78M. The company’s gross m...
STAAR Surgical ( STAA ) stock price surged ~10% to $32.81 in just one day after a massive Q1 earnings beat, extending its monthly rally to around 20% as bulls cheered its strong China recovery and profit improvement. STAAR Surgical reported Q1 non-GAAP EPS of $0.48, beating estimates by $0.40, while revenue surged 119.5% YoY to $93.5M, topping analyst expectations by $14.78M. The company’s gross margin also improved sharply to 73.6% from 65.8% a year ago, helped by better manufacturing efficiency and lower production costs. The company swung back to profit with net income of $5.2M compared to a loss of $(54.2)M last year, while adjusted EBITDA came in at $24.4M, showing strong margin recovery and operating leverage. China remained the biggest growth driver . The sales from the region reached $47.4M as demand for the newly launched EVO+ lenses stayed strong. The management said distributor inventory in China is now fully normalized, meaning growth is being driven by real customer demand instead of inventory restocking. The momentum was not only limited to China. Ex-China sales rose 6% YoY to $46.1M, while U.S. sales jumped 22%, even as the broader refractive surgery market declined 7%. The company also received FDA approval to expand EVO ICL use for patients aged 45-60, opening the door to nearly 8M additional potential patients. Although management did not provide full-year revenue guidance due to macro uncertainty, it expects a strong Q2 and continues targeting around 75% gross margin for FY26. The strong Q1 beat boosted analyst sentiment, with some raising STAAR Surgical 's 12-month price targets from $26 to $40, meaning from 'Neutral' to 'Outperform,' reported Wedbush Securities. The stock has gained 40.49% YTD, outperforming the S&P 500 ( SP500 ) return of 8.75%. However, Wall Street and Seeking Alpha analysts' ratings remain around 'Hold' levels, while Quant ratings currently stand at 3.70, viewing the stock as a 'Buy.' More on STAAR Surgical STAAR Surgical Com...
Earnings Call Insights: Versant Media Group (VSNT) Q1 2026 Management View “We’re off to a strong start to the year with continued progress and growth across key areas of the business, driven by disciplined execution and the strength of our portfolio,” said (CEO & Director Mark Lazarus), adding that the strategy is “anchored in live sports and news” while “accelerating the growth of our digital pl...
Earnings Call Insights: Versant Media Group (VSNT) Q1 2026 Management View “We’re off to a strong start to the year with continued progress and growth across key areas of the business, driven by disciplined execution and the strength of our portfolio,” said (CEO & Director Mark Lazarus), adding that the strategy is “anchored in live sports and news” while “accelerating the growth of our digital platforms.” (CEO & Director Lazarus) pointed to audience momentum across brands, including: CNBC delivering “its highest rated quarter in 4 years,” MS NOW having “its most watched quarter since 2024,” and Golf Channel reaching “13.5 million unique viewers during the week” of the Masters. (CEO & Director Lazarus) said Platforms delivered “high single-digit growth,” driven by “GolfNow and Fandango,” and announced M&A tied to platform expansion: “we acquired StockStory, an AI-driven platform” and cited prior acquisitions “INDY Cinema for Fandango, StockStory for CNBC and Free TV Networks.” (CEO & Director Lazarus) reiterated capital return and said the company announced “an accelerated share repurchase transaction as we enter the second quarter.” “Total revenue for the quarter was approximately $1.69 billion,” said (CFO & COO Anand Kini), and described “robust profitability healthy margins, significant free cash flow generation and continued momentum in Platforms revenue.” Outlook Full-year 2026 guidance reiterated as “$6.15 billion to $6.4 billion in revenue, adjusted EBITDA of $1.85 billion to $2.0 billion and free cash flow of $1.0 billion to $1.2 billion,” said (CFO & COO Kini). (CFO & COO Kini) flagged expected volatility: “We expect quarterly fluctuations driven by content licensing working capital and higher programming costs in the second half, particularly in the fourth quarter.” Versant’s guidance language stayed aligned with the prior quarter’s framework, when (CFO & COO Kini) said, “We expect revenue between $6.15 billion and $6.4 billion,” “adjusted EBITDA between $...
The number of supertankers hauling unsanctioned oil through the Strait of Hormuz has shown signs of rising in recent days, offering limited relief to an oil market that’s suffered the largest supply disruption in history. Four ships each hauling 2 million barrels of mostly-Iraqi crude have exited since May 10 — a rate close to 2 million barrels a day — according to vessel tracking data compiled by...
The number of supertankers hauling unsanctioned oil through the Strait of Hormuz has shown signs of rising in recent days, offering limited relief to an oil market that’s suffered the largest supply disruption in history. Four ships each hauling 2 million barrels of mostly-Iraqi crude have exited since May 10 — a rate close to 2 million barrels a day — according to vessel tracking data compiled by Bloomberg. Still, prior to the war, there were about 20 or so tankers of various sizes crossing the waterway daily. Oil traders are monitoring Hormuz flows closely because the blockage of the waterway has already cut about a billion barrels from global supply. While shipments from countries other than Iran have crept up, those from the Islamic Republic have slumped sharply since an American blockade. In recent weeks, some ships have crossed with their satellite signals off, meaning it’s possible the number increases down the line once those vessels re-emerge away from the Middle East. Hormuz has remained largely blocked since the war began in late February and has been subject to an international diplomatic arm wrestle ever since. Iran earlier this month laid out an updated process for ships wanting to cross Hormuz that involved dealing with a body called the Persian Gulf Strait Authority. At the same time, the US has maintained a blockade, from the edge of the Gulf of Oman, on Iranian ports. That has slowed maritime traffic in the region, though some vessels have been able to cross thanks to agreements between governments. Still, while a handful of tankers have been able to escape, it’s much less clear whether they’ll be willing to return given the risks to shipping. “There’s been an increase but the levels are so low that it won’t make much of a difference,” said Georgios Sakellariou, a freight analyst at Signal Maritime. “The major issue is that even if all the tankers inside leave, new ones won’t be entering anytime soon.” Of the four ships that departed with their sig...
sommart/iStock via Getty Images Three months after my previous coverage, Universal Insurance Holdings, Inc. ( UVE ) stayed strong as the stock price kept increasing to its one-year high. This delivered 16% returns, which justified my P/E target price, or TP, in my previous coverage. And once again, this showed that I may have been too cautious about it. In fact, valuation shows that it still has s...
sommart/iStock via Getty Images Three months after my previous coverage, Universal Insurance Holdings, Inc. ( UVE ) stayed strong as the stock price kept increasing to its one-year high. This delivered 16% returns, which justified my P/E target price, or TP, in my previous coverage. And once again, this showed that I may have been too cautious about it. In fact, valuation shows that it still has some upside potential. However, this makes it more difficult for me to find a truly safe entry point. Growth has started to wane, although we could attribute it to its conservative approach as well. Market aspects are affecting its performance. Technicals are still strong and bullish, but recent overbuying may strengthen selling pressures. UVE Q1 2026: Underwriting Strategies Created Balance In a high-inflation and hurricane-prone environment, property and casualty, or P&C, insurance companies may experience various challenges. But with their strategic pricing and risk diversification efforts, they can stabilize growth and boost profitability. This is what I have noticed about Universal Insurance Holdings, Inc., ever since I started covering it a year ago. Until now, its operational strength persists, although we are seeing the mounting impact of macroeconomic volatility. This was shown in its most recent performance. In Q1 2026, its operating revenue amounted to $393.6M , down by -0.3% YoY from $394.7M. This YoY change was a reversal from my previous coverage, which enjoyed a 3.6% YoY increase in revenue. This was also its weakest performance and the first time it had a negative revenue change in eight quarters. We can attribute it to the valuation or unrealized losses on its investments. This should not be surprising considering the sharp changes in the macroeconomic environment two to three months ago. Meanwhile, its actual insurance operations remained stable as net premiums earned increased by 0.3%. Of course, we cannot deny that growth has waned relative to my previous...
wildpixel/iStock via Getty Images Investment thesis Energy Fuels ( UUUU ) just released its Q1, 2026 results , and the headline is a beat in revenues and a miss in earnings. The company is still losing money, albeit at a slower pace. There is a significant improvement in the company's performance, with growing output. External factors are trending in its favor, complementing its growth stock profi...
wildpixel/iStock via Getty Images Investment thesis Energy Fuels ( UUUU ) just released its Q1, 2026 results , and the headline is a beat in revenues and a miss in earnings. The company is still losing money, albeit at a slower pace. There is a significant improvement in the company's performance, with growing output. External factors are trending in its favor, complementing its growth stock profile. I see this company reaching profitability and establishing itself as a major player in the uranium mining as well as the rare earth industries. With these considerations in mind, I decided to initiate a position in this stock once it went under $20/share. I intend to add to my position on any further pullbacks, on a positive long-term outlook. Moving from a sell to a cautious buy I last covered Energy Fuels stock in early Fall, last year, at which point I decided to take profits on my position, after a strong rally that resulted in gains of over 200%. Energy Fuels stock price & other metrics. (Seeking Alpha) Its share price has moved further up since then, but it also had some sizable dips, reflecting ongoing market uncertainty when it comes to this stock. A great deal of the uncertainty from back then is starting to dissipate. Energy Fuels managed to ramp up uranium output last year, and it is making headway on becoming a major US rare earth minerals producer. The external market conditions are favorable for both uranium & rare earths, making this a growth stock, which in my view is on the verge of becoming steadily profitable within favorable commodities market conditions. My average current cost basis is just slightly lower compared with my September 2025 sell decision, at just over $17/share. For full disclosure, I did make a second trade on the dip in the company's share price in late 2025, and then I sold the rally, so overall, my September 2025 decision proved to be correct. I am increasingly confident that I am making the right decision this time around, in purs...